Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)


  • Data show that HCV therapy with DAAs is highly effective and safe in persons with active or recent IDU and/or who are receiving medication treatment for opioid use disorder, with SVR12 rates exceeding 90% in these populations[Feld 2014; Grebely 2017; Grebely 2016a; Grebely 2016b; Zeuzem 2015; Dore 2016; Foster 2019]
  • Guidelines from both the AASLD and EASL recommend treatment of acute and chronic HCV infection in PWID in conjunction with linkage to harm-reduction strategies[AASLD-IDSA HCV; EASL HCV]
  • Some cases of HCV reinfection should be expected among PWID following curative HCV treatment due to ongoing risk behavior[Simmons 2016]

Action required